This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Relationship Disclosure: Semaglutide Watchdog and its publisher, US Peptides Partners LLC, have no ownership, affiliate, referral, advertising, management, reviewer, or other material financial relationship with certain providers listed on this website. All providers are evaluated using the same documented evidence, pricing, and verification methodology, regardless of relationship status.
The GLP-1 pathway that costs $25 a month
Everyone comparing cash prices should spend twenty minutes on this first. Most do not.
The short version
If your plan covers Zepbound or Wegovy, a manufacturer savings card can bring it to roughly $25. Nothing on the cash market competes.
The analysis
Do this before anything elseCheck your insurance before you compare any cash price. If your plan covers Zepbound or Wegovy, the manufacturer savings card can bring your cost to roughly $25/month — which beats every cash option on this site by an order of magnitude, for an FDA-approved product.
Coverage is most common through employer-sponsored commercial plans. Zepbound is excluded from Medicare Part D for weight loss and from most state Medicaid programmes. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
Coverage is most common through employer-sponsored commercial plans. Zepbound is excluded from Medicare Part D for weight loss and from most state Medicaid programmes. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
| Pathway | Cost | What it does | Status |
|---|---|---|---|
| Brand + commercial coverage + savings card | as low as $25/mo | Zepbound or Wegovy when the plan covers it. Beats every cash path here. | Verified |
| Medicare GLP-1 Bridge (Wegovy) | $50/mo | Eligible Part D members, 1 Jul 2026 - 31 Dec 2027. Prior auth required. | Verified |
| PlushCare | $19.99/mo membership + copay | Cheapest membership in the category. Prior-auth support. $129 initial visit. | Verified |
| Found (insurance option) | $99/mo (12-mo) to $199/mo + ~$30/visit | Free insurance check built in. | Verified |
| Mochi Health | $79/mo membership + copay | Coordinates insurance for brand medication. | Verified |
What a commitment actually costs you
Before you commit to a long planA committed plan lowers the monthly figure and raises the risk. Before you sign one, ask what happens if you stop early — because a meaningful number of people do. Roughly one in five patients discontinues a GLP-1 within the first few months, most often because of gastrointestinal side effects. Others stop because insurance unexpectedly approves a brand product, or because they reach a goal weight, or because their circumstances change.
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Dose escalation: the risk the headline price hides
The question that matters more than the headline priceAsk what you will pay at your target maintenance dose, not at the starting dose. This is the difference between a programme that quotes a flat rate at every dose and one that escalates: MEDVi's compounded tirzepatide reaches $499/month at 10-15mg against a $399 headline; Shed's injectables rise with dose; Oak escalates $50-$75 per step. Over a year, on a full titration, the gap between a flat-rate programme and an escalating one can exceed $3,000 — far more than any difference in the advertised starting price.
| Provider | Price at higher doses | Risk |
|---|---|---|
| NexLife | Same at every covered dose | None — flat rate |
| Mochi Health | Same at all doses | None |
| Enhance.MD | Same at all doses | None |
| Eden | Same at all doses (compounded) | None on compounded |
| TrimRx | Flat ongoing rate | None |
| Oak Longevity | Flat across dosages | None |
| Shed | Increases at higher doses | Material — model at maintenance |
| MEDVi | $399 → $499 at 10-15mg | Material — $1,200/yr swing |
| LillyDirect (brand) | $299 → $449; $699 if you miss the 45-day refill | Material — set a reminder |
The insurance pathway
Do this before anything elseCheck your insurance before you compare any cash price. If your plan covers Zepbound or Wegovy, the manufacturer savings card can bring your cost to roughly $25/month — which beats every cash option on this site by an order of magnitude, for an FDA-approved product.
Coverage is most common through employer-sponsored commercial plans. Zepbound is excluded from Medicare Part D for weight loss and from most state Medicaid programmes. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
Coverage is most common through employer-sponsored commercial plans. Zepbound is excluded from Medicare Part D for weight loss and from most state Medicaid programmes. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
Dose caps: the other thing a low price can hide
A capped dose is not a discountWatch for dose caps as well as dose escalation. Noom Med's $199 compounded semaglutide programme is capped at 0.6mg — the STEP trials that established semaglutide's efficacy used 2.4mg. A capped programme is not a cheaper version of the same treatment; it is a lower-dose treatment, and the expected effect is correspondingly smaller. Noom's full-titration programme is $279.
How to verify any of this yourself
You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
If a provider will not answer questions 4 or 5 in writing, that is itself information.
What to do about it
Three practical steps follow from everything above.
- Check your insurance first. A covered brand prescription with a manufacturer savings card can cost roughly $25 a month, which beats every cash option discussed here.
- Then price the manufacturer directly. LillyDirect and NovoCare sell brand GLP-1s for $149-$449. Several telehealth platforms resell the identical drugs at four to eleven times that.
- Then, and only then, compare compounded programmes — on their ongoing total cost, medication plus any mandatory membership, at the dose you expect to maintain.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Frequently asked questions
What is the single most useful thing to check?
How current is this?
Do you earn commission?
Update history
| Date | What changed |
|---|---|
| July 12, 2026 | Brand pricing re-verified. |
| July 6, 2026 | Provider dataset refreshed. |
Sources
- U.S. Food and Drug Administration — labels, compounding guidance, adverse-event reporting.
- Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare) published self-pay pricing.
- NexLife published program pages, transcribed July 11, 2026.
- Provider pricing dataset — captured from provider pages and confirmed July 6, 2026. Verified.
- Our pricing-verification methodology and source policy.
Verified against Eli Lilly's own pricing pages. Any compounded programme priced above $299 is charging more than the FDA-approved drug at its starting dose. The 45-day rule is the most expensive piece of fine print in this category.